Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LENZ Therapeutics, Inc. Director's Dealing 2021

Jun 25, 2021

32045_dirs_2021-06-24_0d78497d-bc24-4c38-a7ed-c434c62053e1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Graphite Bio, Inc. (GRPH)
CIK: 0001815776
Period of Report: 2021-06-24

Reporting Person: Bassan Abraham (Director)